Udayavni Special

Could still deliver a Covid-19 vaccine in 2020, says Pfizer


PTI, Oct 28, 2020, 11:26 AM IST

Image for representation

New York: Pfizer executives expressed measured optimism Tuesday over the prospect of providing a coronavirus vaccine in 2020 as the pharma giant reported lower third-quarter profits due to disruption in healthcare that dented drug demand.

Pfizer Chief Executive Albert Bourla said the drug giant could supply some 40 million doses in the United States in 2020 if clinical testing proceeds as expected and regulators approve a vaccine.

“If all goes well, we will be ready to distribute an initial number of doses,” said Bourla, who pointed to a US government contract for Pfizer to supply 40 million doses by the end of this year and 100 million doses by March 2021.

But Bourla said the company still had not reached key benchmarks in assessing vaccine efficacy. Pfizer has said previously that it could have the data in October.

Bourla said the company expects to file for emergency use authorization for its Covid-19 vaccine in the third week of November, roughly in line with earlier timetables.

Asked if he was “bullish” the vaccine would work, Bourla said: “I’m not bullish a vaccine will work. I’m cautiously optimistic that the vaccine will work.”

Regarding earnings, Pfizer reported a 71 per cent drop in profit to $2.2 billion. The year-ago period included a large gain connected to a transaction.

Revenues dipped four per cent to $12.1 billion, missing analyst estimates.

Pfizer estimated a revenue hit of $500 million connected to Covid-19 due to lower pharma demand in China and fewer wellness visits from patients in the US.

The company saw an 11 per cent drop in its hospital business in emerging markets, primarily due to fewer elective surgeries in China and shorter in-patient hospital stays in the country.

This effect was partially offset by increased demand for the Prevnar-13 vaccine for pneumonia “resulting from greater vaccine awareness for respiratory illnesses,” the company said.

Pfizer also cited strong performance in its biopharma business due to good sales for cancer drug Ibrance, anticoagulant Eliquis and other medications.

Shares edged up 0.1 per cent to $37.97 in afternoon trading.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Navy finds some debris of crashed MiG-29K in Arabian sea

Serum Institute rejects charges levelled by vaccine trial participant, threatens to seek damages

K’taka COVID-19 update: 1291 new cases, 1530 recoveries, 15 deaths on Nov 28

India ‘pharmacy of world,’ focusing on deeper ties in S&T: Swedish amb

PM hailing farm laws shows govt ‘drunk with power’, ‘rigid’ in face of protests: Cong

UP registers first case under anti-conversion law in Bareilly

Modi’s Hyd visit: A testimony of Telangana achievement, KCR should have been invited, says KTR



Related Articles More

Pope, with new cardinals, warns church against mediocrity

Pandemic calls off Christmas markets in Europe

Barack Obama approves Drake to play him in a potential biopic

Ex-Trump campaign aide sues over Russia probe surveillance

Continuing Chinese construction activities along Indian border ‘provocative measure’: US lawmaker

MUST WATCH

Meet the man with the largest collections of Newspapers | Umesh Rao Ekkar Mangalore

Mangalore: Woman rescues a cat from 30 feet deep well | Ranjini Shetty | Udayavani

CM and central leadership will take final call on Cabinet expansion: Ashwath Narayan

Assorted flowers, fruits, and vegetables are grown in the terrace garden

Celebrating 25 Years of Laveena Masala | Since 1996 | Udayavani

Latest Additions

Navy finds some debris of crashed MiG-29K in Arabian sea

Serum Institute rejects charges levelled by vaccine trial participant, threatens to seek damages

Will Hold Punjab CM Responsible if Farmers’ Gatherings Aggravate Covid in Haryana, Says Khattar

High Octane Campaign for Hyderabad Polls Ends; 67 Lakh Voters to Decide Fate of 1,222 Candidates on Dec 1

K’taka COVID-19 update: 1291 new cases, 1530 recoveries, 15 deaths on Nov 28

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.